MBBS, Ph.D., Group Medical Director, GRAIL
Richard T. Williams, MBBS PhD, is Group Medical Director at GRAIL and serves as project lead for GRAIL’s Circulating Cell-Free Genome Atlas (CCGA) Study, which will characterize the landscape of circulating cell-free nucleic acid profiles in several thousand individuals with cancer and in thousands of healthy non-cancer participants using GRAIL’s “high-intensity” (ultra-broad and ultra-deep) sequencing approach. Dr Williams earned both his medical degree (MBBS) and PhD degrees at the University of Queensland, Australia and then undertook pediatric residency training (Royal Children’s Hospital, Melbourne, Australia), and pediatric hematology & oncology fellowship and further laboratory training at St Jude Children’s Research Hospital, Memphis, TN. At St Jude, he later established and led an independent translational cancer genetics laboratory program. Over the last several years, he has held positions of increasing responsibility for oncology therapeutic programs in Amgen’s Global Development function, at Puma Biotechnology, and most recently as interim Head of Early Development Oncology at Amgen.
Presentation Title and Company Description
Liquid Biopsy Showcase: GRAIL’s Approach to Early Cancer Detection
GRAIL is a life sciences company whose mission is to detect cancer early when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical studies, and state of the art computer science and data science to enhance the scientific understanding of cancer biology and develop blood tests for early-stage cancer detection. For more information, please visit www.grail.com.